ADGRL4 and neoplasm: On the other hand, anti‐ELTD1 and combined therapies were all successful in significantly decreasing TRPM8 positivity staining within the tumour region (anti‐ELTD1: UT *p = 0.0132, bevacizumab **p = 0.0045; combined: UT **p = 0.0095, bevacizumab **p = 0.0034) (Figure 5D–H).